Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Relmada Therapeutics, a late-stage biotechnology company focusing on CNS diseases, announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with CEO Sergio Traversa and CFO Maged Shenouda on June 6, 2024, at 7:30am ET in New York, NY. The management team will also host one-on-one investor meetings during the conference. The fireside chat will be webcast live and accessible through the Investors section of Relmada's website, with an archived replay available for 30 days post-event.
- Relmada's participation in a prestigious event like the Jefferies Global Healthcare Conference enhances its visibility among investors.
- The webcast allows broader access to management insights, potentially attracting more investors.
- One-on-one investor meetings may lead to stronger investor relations and potential new investments.
- No new clinical or financial data were disclosed, which might be seen as a lack of substantial updates.
- The announcement does not provide insights into the company's recent performance or pipeline progress, leaving investors with new information.
2024 Jefferies Global Healthcare Conference
Format: Fireside chat
Presentation Date: Thursday, June 6, 2024, 7:30am ET
Webcast: Click Here
Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.
The webcast can also be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors. An archived replay will be available for 30 days following the conclusion of the event.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada's ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully carried out, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-the-2024-jefferies-global-healthcare-conference-302161512.html
SOURCE Relmada Therapeutics, Inc.
FAQ
When will Relmada Therapeutics participate in the 2024 Jefferies Global Healthcare Conference?
Who from Relmada Therapeutics will be speaking at the 2024 Jefferies Global Healthcare Conference?
How can I access the webcast of Relmada Therapeutics' presentation at the 2024 Jefferies Global Healthcare Conference?
Will there be an archived replay of Relmada Therapeutics' presentation at the 2024 Jefferies Global Healthcare Conference?
Is Relmada Therapeutics hosting investor meetings at the 2024 Jefferies Global Healthcare Conference?
